Schedule 13G Filing by Dr. Alon Silberman for N2OFF, Inc.

Dr. Alon Silberman, a citizen of Israel and the Chief Executive Officer of MitoCareX Bio Ltd., a wholly owned subsidiary of N2OFF, Inc., has filed a Schedule 13G with the SEC. The filing discloses that Dr. Silberman beneficially owns 454,127 shares of common stock in N2OFF, Inc., representing 16.93% of the total outstanding shares. The shares were acquired as part of the Securities Purchase and Exchange Agreement, as amended, dated February 25, 2025. The filing certifies that the securities were not acquired for the purpose of influencing the control of the issuer and were not held in connection with any transaction having that purpose or effect. The filing is made pursuant to Rule 13d-1(c) and is effective as of October 20, 2025.